Genentech reiterated at outperform by RBC

RBC Capital Markets analyst Jason Kantor rated Genentech, Inc. at outperform, average risk. RBC believes Genentech will post a strong second quarter driven by sales of Avastin, Rituxan and Herceptin. As a result, the analyst is raising its earnings per share to $0.49 from $0.47, above consensus of $0.46. Shares of the South San Francisco, Calif.-based biotherapeutic company were up $1.67, or 2.08%, at $81.80 on volume of 5,836,300 shares versus the three-month running average of 3,465,520 shares. NYSE: DNA)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.